Line-field optical coherence tomography: In vivo diagnosis of basal cell carcinoma subtypes compared to histopathology.

Bookmark this %label%

Basal cell carcinoma (BCC) is the most common skin cancer in the general population. Treatments vary from Mohs surgery to topical therapy, depending on the subtype. Dermoscopy, reflectance confocal microscopy […]

» Read more

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.

Bookmark this %label%

Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has demonstrated […]

» Read more

Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research, part 2 (the OCOMEN project).

Bookmark this %label%

Congenital melanocytic naevi (CMN) can have a great impact on patients’ lives due to perceived stigmatization and the risk of melanoma development and neurological complications. Development of a core outcome […]

» Read more

Systematic Review and Meta-Analysis of Local Recurrence Rates of Head and Neck Cutaneous Melanomas after Wide Local Excision, Mohs Micrographic Surgery, or Staged Excision.

Bookmark this %label%

Prospective trials have not compared local recurrence rates for different excision techniques for cutaneous melanomas on the head and neck.To determine local recurrence rates of cutaneous head and neck melanoma […]

» Read more

Views on Mobile Health Apps for Skin Cancer Screening in the General Population: An In-Depth Qualitative Exploration of Perceived Barriers and Facilitators.

Bookmark this %label%

Mobile health (mHealth) applications (apps) integrated with artificial Intelligence (AI) for skin cancer screening are increasingly reimbursed by health insurers. However, an in-depth exploration of the general public’s views towards […]

» Read more

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

Bookmark this %label%

Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and […]

» Read more

Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.

Bookmark this %label%

Clinical practice guidelines (CPGs), statements that include recommendations intended to optimise patient care, play a critical role in standardising and improving treatment outcomes based on best evidence. It is currently […]

» Read more

Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.

Bookmark this %label%

Approximately 85% of melanoma patients who undergo a sentinel lymph node biopsy (SLNB) are node-negative. Melanoma incidence is highest in patients ≥65 years, but their SLNB positivity rate is lower than […]

» Read more

Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3+ resident memory CD8+ T cells and multiple chemokine pathways.

Bookmark this %label%

The use of immune checkpoint inhibitors (ICI), such as anti-programmed cell death-1 (PD-1) antibodies, has profoundly changed melanoma prognosis. However, only 35% to 45% of patients experience durable responses, highlighting […]

» Read more

Limitations in the Literature Regarding Mohs Surgery and Staged Excision for Melanoma: A Critical Review of Quality and Data Reporting.

Bookmark this %label%

The literature supporting Mohs micrographic surgery (MMS) and staged excision (SE) in treating primary cutaneous melanoma is growing but has not been critically reviewed for bias.Articles concerning MMS/SE for melanoma […]

» Read more

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Bookmark this %label%

The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved […]

» Read more

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Bookmark this %label%

The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo […]

» Read more

Dynamic dermoscopic and reflectance confocal microscopic changes of melanocytic lesions excised during follow-up.

Bookmark this %label%

Digital dermoscopy follow-up (DDF) is useful in improving melanoma recognition, catching early changes over time, although benign nevi can also show changes. Reflectance confocal microscopy (RCM) improves melanoma diagnostic accuracy […]

» Read more

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis.

Bookmark this %label%

A variety of dermatoses have been reported in the growing number of patients treated with immune checkpoint inhibitors (ICIs), but the current understanding of cutaneous immune related adverse events (irAEs) […]

» Read more

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

Bookmark this %label%

IrAEs typically occur within 4 months of starting anti-PD1-based therapy (anti-PD1 +/- anti-CTLA4), but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature […]

» Read more

The Association between Citrus Consumption and Melanoma Risk in the UK Biobank.

Bookmark this %label%

Melanoma incidence has been dramatically increasing worldwide. Psoralen, a known photocarcinogen, is naturally abundant in citrus products, leading to the hypothesis that high citrus consumption may increase melanoma risk.To investigate […]

» Read more

ONCOLYTIC VIRUS IN GLIOMAS: A REVIEW OF HUMAN CLINICAL INVESTIGATIONS.

Bookmark this %label%

Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to […]

» Read more

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

Bookmark this %label%

Guidelines for pathologic evaluation of neoadjuvant specimens and pathologic response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the OpACIN-neo clinical trial of neoadjuvant […]

» Read more

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Bookmark this %label%

High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic […]

» Read more
1 2 3 15